Regístrese
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Nuevos tratamientos en la diabetes mellitus
Información de la revista
Vol. 48. Núm. 6.
Páginas 174-176 (Junio 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 48. Núm. 6.
Páginas 174-176 (Junio 2001)
DOI: 10.1016/S1575-0922(01)74385-9
Acceso a texto completo
Nuevos tratamientos en la diabetes mellitus
New therapies in diabetes mellitus
Visitas
2668
E. Faure Nogueras*
Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario de Zaragoza
Este artículo ha recibido
2668
Visitas
Información del artículo

La diabetes tipo 2 es una enfermedad heterogénea en la que se asocia la resistencia a la insulina y el déficit relativo y posteriormente absoluto de insulina.

Recientemente se han descrito una serie de fármacos capaces de disminuir la glicemia posprandial de los pacientes diabéticos así como disminuir las concentraciones de HbA1c y mejorar el control metabólico. La repaglinida y la nateglinida actúan aumentando la secreción de insulina.

Entre las tiazolidenedionas se han utilizado la toglitazona, la rosiglitazona y la pioglitazona. Su mecanismo de accion es estimulando los receptores de la PPAR-γ y activando la entrada de glucosa.

La experiencia sobre estos fármacos es limitada. Parece que la pioglitazona y la rosiglitazona tienen menos efectos secundarios que los descritos para la toglitazona (hepatotoxicidad).

Dichos fármacos pueden utilizarse en combinación con la insulina o con la metformina.

Palabras clave:
Diabetes mellitus
Repaglinida
Nateglinida
Toglitazona
Rosiglitazona
Pioglitazona

Type 2 diabetes is an heterogeneous disease in which development contributes insulin resistance and insulin sensitivity.

In order to reduce post-prandial hyperglycemia in these patients, a group of new drugs have been considered as a therapeutic tool for decreasing HbA1c and reaching a better metabolic control. Repaglinide and Nateglinide have been used to increase insulin secretion.

Other new drugs such as Toglitazone, Rosiglitazone and Pioglitazone have been described recently. Their mechanism of action is stimulating the PPAR-γ receptors which produces an activation of glucose uptake. These drugs can be used with Metformin which mainly acts by inhibiting the hepatic glucose production.

In spite of that, there is limited experience with these drugs. It seems that Pioglitazone and Rosiglitazone have considerably fewer side effects as described for Toglitazone (Hepatotoxicity). Thus, these drugs can be used in combination with insulin or another insulin sensitizer as Metformin.

Key words:
Diabetes mellitus
Repaglinide
Nateglinide
Toglitazone
Rosiglitazone
Pioglitazone
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.A. DeFronzo, R.C. Bonadonna, E. Ferranini.
Pathogenesis of NIDDM.
Diabetes Care, 15 (1992), pp. 318-368
[2.]
Y. Kruszynskay.
Metabolic disturbances in diabetes mellitus.
Textbook of diabetes, pp. 1-25
[3.]
L. Rossetti, A. Giaccari, R.A. DeFronzo.
Glucose toxicity.
Diabetes Care, 13 (1990), pp. 610-630
[4.]
B. Kahn, GJI Shulman, R.A. DeFronzo, S.W. Cushman, L. Rossetti.
Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin resistant glucose transport in adipose cells without restoring glucose transporter gene expression.
J Clin Invest, 87 (1991), pp. 561-570
[5.]
M. Hanefeld.
Risk factors for myocardial infarction and death in newly detected NIDDM. The Diabetes Intervention Study, 11-year follow-up.
Diabetologia, 39 (1996), pp. 1577-1583
[6.]
A. Avignon, A. Radauceanu, L. Monnier.
Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes.
Diabetes Care, 20 (1997), pp. 1822-1826
[7.]
D.R. Owens.
Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs.
Diabetic Med, 15 (1998), pp. 28-36
[8.]
R.E. Ratner.
Replaglinide therapy in the treatment of type 2 diabetes.
Today's Ther Trends, 17 (1999), pp. 57-66
[9.]
P. Dansbo, T.C. Marbury, V. Hatorp, P. Clauson, P. Muller.
Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
Diab Res Clin Pract, 45 (1999), pp. 31-39
[10.]
R.B. Goldberg, D. Einohorn, C.P. Lucas, M. Rendell, P. Damsbo, W.C. Huang, et al.
A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.
Diabetes Care, 21 (1998), pp. 1897-1903
[11.]
P. Damsbo, P. Clauson, T.C. Marbury, K. Windfeld.
A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Diabetes Care, 22 (1999), pp. 789-794
[12.]
R. Moses, R. Slobodniuk, S. Boyages, S. Colagiuri, W. Kidson, J. Carter, et al.
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care, 22 (1999), pp. 119-124
[13.]
L. Keilson, S. Mather, Y.H. Walter, S. Subramanian, J. McLeod.
Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J.
Clin End Metab, 85 (2000), pp. 1081-1086
[14.]
M. Hanefeld, K.P. Bouter, S. Dickinson, C. Guitard.
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Diabetes Care, 23 (2000), pp. 202-206
[15.]
J. Horton, S. Cunkingbeard, M. Gatlin, J. Foley, S. Mallows, S. Shen.
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Diabetes Care, 23 (2000), pp. 1660-1665
[16.]
J. Vamecq, N. Latruffe.
Medical significance of peroxisome proliferatoractivated receptors.
[17.]
K. Schoonjans, J. Auwerx.
Thiazolidinediones: an update.
Lancet, 355 (2000), pp. 1008-1010
[18.]
A. Shimaya, E. Kurosaki, K. Shioduka, R. Nakano, M. Shibasaki, H. Shikama.
YM2668 increase the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-LI adipocytes.
Horm Metab Res, 30 (1998), pp. 543-548
[19.]
I.M. El-Kebbi, S. Roser, R.J. Pollet.
Regulation of glucose transport by pioglitazones in cultured muscle cells.
Metabolism, 43 (1994), pp. 953-958
[20.]
S.C. Souza, M.T. Yamamoto, M.D. Franciosa, P. Lien, A.S. Greenberg.
BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin. sensitizing mechanism for thiazolidinediones.
Diabetes, 47 (1998), pp. 691-695
[21.]
D. Maggs, T.A. Buchanan, C. Burant, G. Cline, B. Gumbiner, W.A. Hsueh, et al.
Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus.
Ann Intern Med, 128 (1998), pp. 176-185
[22.]
J. Yu, Y.T. Kruszynska, M.I. Mulford, J. Olefsky.
A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Diabetes, 48 (1999), pp. 2411-2421
[23.]
W. Fonseca, T. Valiquett, J. Huang, M. Shazzi, W. Randall, R. Whitcomb.
Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized controlled study.
J Clin Endocrinol Metab, 83 (1998), pp. 3169-3176
[24.]
S. Aronof, S. Rosenblat, S. Brithwaite, S. Egan, A. Mathisen, R. Schnider.
Pioglitazone study group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes.
Diabetes Care, 23 (2000), pp. 1605-1611
[25.]
Y. Iwamoto, K. Kosaka, T. Kuzuya, Y. Akanuma, Y. Shigeta, T. Kaneko.
Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
[26.]
T. Antonucci, R. Whitcomb, R. McLain, D. Lockwood.
Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
Diabetes Care, 20 (1997), pp. 188-193
[27.]
J. Schwartz, P.H. Raskin, J. Fonseca, M.J. Graveline.
Effect of troglitazone in insulintreated patients with type II diabetes mellitus.
N Engl J Med, 38 (1998), pp. 861-866
[28.]
L.M. Forman, D.A. Simmons, R.H. Diamond.
Hepatic failure in a patient taking rosiglitazone.
Ann Intern Med, 132 (2000), pp. 118-121
[29.]
P. Tontonoz, L. Nagy.
Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications form cardiovascular disease.
Curr Opin Lipidol, 10 (1999), pp. 485-490
[30.]
J. Auwerx.
PPAR-γ, the ultimate thrifty gene.
Diabetologia, 42 (1999), pp. 1033-1049
[31.]
W. Hsueh, S. Jackson, R. Law.
Control of vascular cell proliferation and migration by PPAR-γ.
Diabetes Care, 24 (2001), pp. 392-397
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.